Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

Underweight, but Not Obesity, Linked to Glaucoma Progression

A higher body mass index (BMI) was significantly associated with slower rates of retinal nerve fiber layer change among patients with glaucoma, while those with

April 23, 2024

Live from the 2023 STAT Summit

What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how do you pronounce “Bayer”? We cover all that and more

October 19, 2023

Why do we blush, and what are the underlying mechanisms of blushing? Research aims to find out

Researchers investigated the neural substrates and mental processes underlying blushing in response to self-observation.

July 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.